Prolonged COVID-19 symptom duration in people with systemic autoimmune rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey

Michael Diiorio; Kevin Kennedy; Jean W. Liew; Michael S. Putman; Emily Sirotich; Sebastian E. Sattui; Gary Foster; Carly Harrison; Maggie J. Larché; Mitchell Levine; Tarin T. Moni; Lehana Thabane; Suleman Bhana; Wendy Costello; Rebecca Grainger; Pedro M. MacHado; Philip C. Robinson; Paul Sufka; Zachary S. Wallace; Jinoos Yazdany; Monique Gore-Massy; Richard A. Howard; More A. Kodhek; Nadine Lalonde; Laura Ann Tomasella; John Wallace; Akpabio Akpabio; Deshiré Alpízar-Rodríguez; Richard P. Beesley; Francis Berenbaum; Inita Bulina; Eugenia Yupei Chock; Richard Conway; Alí Duarte-García; Eimear Duff; Tamer A. Gheita; Elizabeth R. Graef; Evelyn Hsieh; Lina El Kibbi; David F.L. Liew; Chieh Lo; Michal Nudel; Aman Dev Singh; Jasvinder A. Singh; Namrata Singh; Manuel F. Ugarte-Gil; Jonathan S. Hausmann; Julia F. Simard; Jeffrey A. Sparks

doi:10.1136/rmdopen-2022-002587

Prolonged COVID-19 symptom duration in people with systemic autoimmune rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey

Michael Diiorio, Kevin Kennedy, Jean W. Liew, Michael S. Putman, Emily Sirotich, Sebastian E. Sattui, Gary Foster, Carly Harrison, Maggie J. Larché, Mitchell Levine, Tarin T. Moni, Lehana Thabane, Suleman Bhana, Wendy Costello, Rebecca Grainger, Pedro M. MacHado, Philip C. Robinson, Paul Sufka, Zachary S. Wallace, Jinoos YazdanyMonique Gore-Massy, Richard A. Howard, More A. Kodhek, Nadine Lalonde, Laura Ann Tomasella, John Wallace, Akpabio Akpabio, Deshiré Alpízar-Rodríguez, Richard P. Beesley, Francis Berenbaum, Inita Bulina, Eugenia Yupei Chock, Richard Conway, Alí Duarte-García, Eimear Duff, Tamer A. Gheita, Elizabeth R. Graef, Evelyn Hsieh, Lina El Kibbi, David F.L. Liew, Chieh Lo, Michal Nudel, Aman Dev Singh, Jasvinder A. Singh, Namrata Singh, Manuel F. Ugarte-Gil, Jonathan S. Hausmann, Julia F. Simard, Jeffrey A. Sparks

Producción científica: Contribución a una revista › Artículo › revisión exhaustiva

24 Citas (Scopus)

Resumen

Objective We investigated prolonged COVID-19 symptom duration, defined as lasting 28 days or longer, among people with systemic autoimmune rheumatic diseases (SARDs). Methods We analysed data from the COVID-19 Global Rheumatology Alliance Vaccine Survey (2 April 2021-15 October 2021) to identify people with SARDs reporting test-confirmed COVID-19. Participants reported COVID-19 severity and symptom duration, sociodemographics and clinical characteristics. We reported the proportion experiencing prolonged symptom duration and investigated associations with baseline characteristics using logistic regression. Results We identified 441 respondents with SARDs and COVID-19 (mean age 48.2 years, 83.7% female, 39.5% rheumatoid arthritis). The median COVID-19 symptom duration was 15 days (IQR 7, 25). Overall, 107 (24.2%) respondents had prolonged symptom duration (≥28 days); 42/429 (9.8%) reported symptoms lasting ≥90 days. Factors associated with higher odds of prolonged symptom duration included: hospitalisation for COVID-19 vs not hospitalised and mild acute symptoms (age-adjusted OR (aOR) 6.49, 95% CI 3.03 to 14.1), comorbidity count (aOR 1.11 per comorbidity, 95% CI 1.02 to 1.21) and osteoarthritis (aOR 2.11, 95% CI 1.01 to 4.27). COVID-19 onset in 2021 vs June 2020 or earlier was associated with lower odds of prolonged symptom duration (aOR 0.42, 95% CI 0.21 to 0.81). Conclusion Most people with SARDs had complete symptom resolution by day 15 after COVID-19 onset. However, about 1 in 4 experienced COVID-19 symptom duration 28 days or longer; 1 in 10 experienced symptoms 90 days or longer. Future studies are needed to investigate the possible relationships between immunomodulating medications, SARD type/flare, vaccine doses and novel viral variants with prolonged COVID-19 symptoms and other postacute sequelae of COVID-19 among people with SARDs.

Idioma original	Inglés
Número de artículo	e002587
Publicación	RMD Open
Volumen	8
N.º	2
DOI	https://doi.org/10.1136/rmdopen-2022-002587
Estado	Publicada - 14 set. 2022

ODS de las Naciones Unidas

Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

Acceder al documento

10.1136/rmdopen-2022-002587

Otros archivos y enlaces

Enlace a la publicación en Scopus

Citar esto

Diiorio, M., Kennedy, K., Liew, J. W., Putman, M. S., Sirotich, E., Sattui, S. E., Foster, G., Harrison, C., Larché, M. J., Levine, M., Moni, T. T., Thabane, L., Bhana, S., Costello, W., Grainger, R., MacHado, P. M., Robinson, P. C., Sufka, P., Wallace, Z. S., ... Sparks, J. A. (2022). Prolonged COVID-19 symptom duration in people with systemic autoimmune rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. RMD Open, 8(2), Artículo e002587. https://doi.org/10.1136/rmdopen-2022-002587

@article{93e0db02a1dc4e61b0048fbe61b53676,

title = "Prolonged COVID-19 symptom duration in people with systemic autoimmune rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey",

abstract = "Objective We investigated prolonged COVID-19 symptom duration, defined as lasting 28 days or longer, among people with systemic autoimmune rheumatic diseases (SARDs). Methods We analysed data from the COVID-19 Global Rheumatology Alliance Vaccine Survey (2 April 2021-15 October 2021) to identify people with SARDs reporting test-confirmed COVID-19. Participants reported COVID-19 severity and symptom duration, sociodemographics and clinical characteristics. We reported the proportion experiencing prolonged symptom duration and investigated associations with baseline characteristics using logistic regression. Results We identified 441 respondents with SARDs and COVID-19 (mean age 48.2 years, 83.7% female, 39.5% rheumatoid arthritis). The median COVID-19 symptom duration was 15 days (IQR 7, 25). Overall, 107 (24.2%) respondents had prolonged symptom duration (≥28 days); 42/429 (9.8%) reported symptoms lasting ≥90 days. Factors associated with higher odds of prolonged symptom duration included: hospitalisation for COVID-19 vs not hospitalised and mild acute symptoms (age-adjusted OR (aOR) 6.49, 95% CI 3.03 to 14.1), comorbidity count (aOR 1.11 per comorbidity, 95% CI 1.02 to 1.21) and osteoarthritis (aOR 2.11, 95% CI 1.01 to 4.27). COVID-19 onset in 2021 vs June 2020 or earlier was associated with lower odds of prolonged symptom duration (aOR 0.42, 95% CI 0.21 to 0.81). Conclusion Most people with SARDs had complete symptom resolution by day 15 after COVID-19 onset. However, about 1 in 4 experienced COVID-19 symptom duration 28 days or longer; 1 in 10 experienced symptoms 90 days or longer. Future studies are needed to investigate the possible relationships between immunomodulating medications, SARD type/flare, vaccine doses and novel viral variants with prolonged COVID-19 symptoms and other postacute sequelae of COVID-19 among people with SARDs.",

keywords = "COVID-19, inflammation, patient reported outcome measures, vaccination",

author = "Michael Diiorio and Kevin Kennedy and Liew, {Jean W.} and Putman, {Michael S.} and Emily Sirotich and Sattui, {Sebastian E.} and Gary Foster and Carly Harrison and Larch{\'e}, {Maggie J.} and Mitchell Levine and Moni, {Tarin T.} and Lehana Thabane and Suleman Bhana and Wendy Costello and Rebecca Grainger and MacHado, {Pedro M.} and Robinson, {Philip C.} and Paul Sufka and Wallace, {Zachary S.} and Jinoos Yazdany and Monique Gore-Massy and Howard, {Richard A.} and Kodhek, {More A.} and Nadine Lalonde and Tomasella, {Laura Ann} and John Wallace and Akpabio Akpabio and Deshir{\'e} Alp{\'i}zar-Rodr{\'i}guez and Beesley, {Richard P.} and Francis Berenbaum and Inita Bulina and Chock, {Eugenia Yupei} and Richard Conway and Al{\'i} Duarte-Garc{\'i}a and Eimear Duff and Gheita, {Tamer A.} and Graef, {Elizabeth R.} and Evelyn Hsieh and {El Kibbi}, Lina and Liew, {David F.L.} and Chieh Lo and Michal Nudel and Singh, {Aman Dev} and Singh, {Jasvinder A.} and Namrata Singh and Ugarte-Gil, {Manuel F.} and Hausmann, {Jonathan S.} and Simard, {Julia F.} and Sparks, {Jeffrey A.}",

note = "Publisher Copyright: {\textcopyright} ",

year = "2022",

month = sep,

day = "14",

doi = "10.1136/rmdopen-2022-002587",

language = "Ingl{\'e}s",

volume = "8",

journal = "RMD Open",

issn = "2056-5933",

publisher = "BMJ Publishing Group",

number = "2",

}

Diiorio, M, Kennedy, K, Liew, JW, Putman, MS, Sirotich, E, Sattui, SE, Foster, G, Harrison, C, Larché, MJ, Levine, M, Moni, TT, Thabane, L, Bhana, S, Costello, W, Grainger, R, MacHado, PM, Robinson, PC, Sufka, P, Wallace, ZS, Yazdany, J, Gore-Massy, M, Howard, RA, Kodhek, MA, Lalonde, N, Tomasella, LA, Wallace, J, Akpabio, A, Alpízar-Rodríguez, D, Beesley, RP, Berenbaum, F, Bulina, I, Chock, EY, Conway, R, Duarte-García, A, Duff, E, Gheita, TA, Graef, ER, Hsieh, E, El Kibbi, L, Liew, DFL, Lo, C, Nudel, M, Singh, AD, Singh, JA, Singh, N, Ugarte-Gil, MF, Hausmann, JS, Simard, JF & Sparks, JA 2022, 'Prolonged COVID-19 symptom duration in people with systemic autoimmune rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey', RMD Open, vol. 8, n.º 2, e002587. https://doi.org/10.1136/rmdopen-2022-002587

TY - JOUR

T1 - Prolonged COVID-19 symptom duration in people with systemic autoimmune rheumatic diseases

T2 - results from the COVID-19 Global Rheumatology Alliance Vaccine Survey

AU - Diiorio, Michael

AU - Kennedy, Kevin

AU - Liew, Jean W.

AU - Putman, Michael S.

AU - Sirotich, Emily

AU - Sattui, Sebastian E.

AU - Foster, Gary

AU - Harrison, Carly

AU - Larché, Maggie J.

AU - Levine, Mitchell

AU - Moni, Tarin T.

AU - Thabane, Lehana

AU - Bhana, Suleman

AU - Costello, Wendy

AU - Grainger, Rebecca

AU - MacHado, Pedro M.

AU - Robinson, Philip C.

AU - Sufka, Paul

AU - Wallace, Zachary S.

AU - Yazdany, Jinoos

AU - Gore-Massy, Monique

AU - Howard, Richard A.

AU - Kodhek, More A.

AU - Lalonde, Nadine

AU - Tomasella, Laura Ann

AU - Wallace, John

AU - Akpabio, Akpabio

AU - Alpízar-Rodríguez, Deshiré

AU - Beesley, Richard P.

AU - Berenbaum, Francis

AU - Bulina, Inita

AU - Chock, Eugenia Yupei

AU - Conway, Richard

AU - Duarte-García, Alí

AU - Duff, Eimear

AU - Gheita, Tamer A.

AU - Graef, Elizabeth R.

AU - Hsieh, Evelyn

AU - El Kibbi, Lina

AU - Liew, David F.L.

AU - Lo, Chieh

AU - Nudel, Michal

AU - Singh, Aman Dev

AU - Singh, Jasvinder A.

AU - Singh, Namrata

AU - Ugarte-Gil, Manuel F.

AU - Hausmann, Jonathan S.

AU - Simard, Julia F.

AU - Sparks, Jeffrey A.

PY - 2022/9/14

Y1 - 2022/9/14

N2 - Objective We investigated prolonged COVID-19 symptom duration, defined as lasting 28 days or longer, among people with systemic autoimmune rheumatic diseases (SARDs). Methods We analysed data from the COVID-19 Global Rheumatology Alliance Vaccine Survey (2 April 2021-15 October 2021) to identify people with SARDs reporting test-confirmed COVID-19. Participants reported COVID-19 severity and symptom duration, sociodemographics and clinical characteristics. We reported the proportion experiencing prolonged symptom duration and investigated associations with baseline characteristics using logistic regression. Results We identified 441 respondents with SARDs and COVID-19 (mean age 48.2 years, 83.7% female, 39.5% rheumatoid arthritis). The median COVID-19 symptom duration was 15 days (IQR 7, 25). Overall, 107 (24.2%) respondents had prolonged symptom duration (≥28 days); 42/429 (9.8%) reported symptoms lasting ≥90 days. Factors associated with higher odds of prolonged symptom duration included: hospitalisation for COVID-19 vs not hospitalised and mild acute symptoms (age-adjusted OR (aOR) 6.49, 95% CI 3.03 to 14.1), comorbidity count (aOR 1.11 per comorbidity, 95% CI 1.02 to 1.21) and osteoarthritis (aOR 2.11, 95% CI 1.01 to 4.27). COVID-19 onset in 2021 vs June 2020 or earlier was associated with lower odds of prolonged symptom duration (aOR 0.42, 95% CI 0.21 to 0.81). Conclusion Most people with SARDs had complete symptom resolution by day 15 after COVID-19 onset. However, about 1 in 4 experienced COVID-19 symptom duration 28 days or longer; 1 in 10 experienced symptoms 90 days or longer. Future studies are needed to investigate the possible relationships between immunomodulating medications, SARD type/flare, vaccine doses and novel viral variants with prolonged COVID-19 symptoms and other postacute sequelae of COVID-19 among people with SARDs.

AB - Objective We investigated prolonged COVID-19 symptom duration, defined as lasting 28 days or longer, among people with systemic autoimmune rheumatic diseases (SARDs). Methods We analysed data from the COVID-19 Global Rheumatology Alliance Vaccine Survey (2 April 2021-15 October 2021) to identify people with SARDs reporting test-confirmed COVID-19. Participants reported COVID-19 severity and symptom duration, sociodemographics and clinical characteristics. We reported the proportion experiencing prolonged symptom duration and investigated associations with baseline characteristics using logistic regression. Results We identified 441 respondents with SARDs and COVID-19 (mean age 48.2 years, 83.7% female, 39.5% rheumatoid arthritis). The median COVID-19 symptom duration was 15 days (IQR 7, 25). Overall, 107 (24.2%) respondents had prolonged symptom duration (≥28 days); 42/429 (9.8%) reported symptoms lasting ≥90 days. Factors associated with higher odds of prolonged symptom duration included: hospitalisation for COVID-19 vs not hospitalised and mild acute symptoms (age-adjusted OR (aOR) 6.49, 95% CI 3.03 to 14.1), comorbidity count (aOR 1.11 per comorbidity, 95% CI 1.02 to 1.21) and osteoarthritis (aOR 2.11, 95% CI 1.01 to 4.27). COVID-19 onset in 2021 vs June 2020 or earlier was associated with lower odds of prolonged symptom duration (aOR 0.42, 95% CI 0.21 to 0.81). Conclusion Most people with SARDs had complete symptom resolution by day 15 after COVID-19 onset. However, about 1 in 4 experienced COVID-19 symptom duration 28 days or longer; 1 in 10 experienced symptoms 90 days or longer. Future studies are needed to investigate the possible relationships between immunomodulating medications, SARD type/flare, vaccine doses and novel viral variants with prolonged COVID-19 symptoms and other postacute sequelae of COVID-19 among people with SARDs.

KW - COVID-19

KW - inflammation

KW - patient reported outcome measures

KW - vaccination

UR - http://www.scopus.com/inward/record.url?scp=85137857593&partnerID=8YFLogxK

U2 - 10.1136/rmdopen-2022-002587

DO - 10.1136/rmdopen-2022-002587

M3 - Artículo

C2 - 36104117

AN - SCOPUS:85137857593

SN - 2056-5933

VL - 8

JO - RMD Open

JF - RMD Open

IS - 2

M1 - e002587

ER -

Prolonged COVID-19 symptom duration in people with systemic autoimmune rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey

Resumen

ODS de las Naciones Unidas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto